Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study

PURPOSE: To investigate the survival benefit with first/second generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) and osimertinib in different treatment sequences. METHODS: We retrospectively screened 3807 patients diagnosed with cancer between 2013 and 2019 at Kaohsi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chin‐Chou, Lai, Chien‐Hao, Chang, Yu‐Ping, Chang, Huang‐Chih, Tseng, Chia‐Cheng, Huang, Kuo‐Tung, Lin, Meng‐Chih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636197/
https://www.ncbi.nlm.nih.gov/pubmed/34704378
http://dx.doi.org/10.1111/1759-7714.14198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636197/
https://www.ncbi.nlm.nih.gov/pubmed/34704378
http://dx.doi.org/10.1111/1759-7714.14198

Ejemplares similares